Cell Signaling Technology Logo - Extra Large
查看特别推荐 >>
  1. Products /
  2. Primary Antibodies /
  3. LMO2 (E8K6I) Rabbit Monoclonal Antibody
Trial Size Available Flag
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

LMO2 (E8K6I) Rabbit Monoclonal Antibody #87182

Filter:
  • WB
  • IF
  • F
  • ChIP

    Product Specifications

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 18
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IF-Immunofluorescence 
    • F-Flow Cytometry 
    • ChIP-Chromatin Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    For optimal ChIP and ChIP-seq results, use 5 μL of antibody and 10 μg of chromatin (approximately 4 x 10^6 cells) per IP. This antibody has been validated using SimpleChIP® Enzymatic Chromatin IP Kits.
    Application Dilution
    Western Blotting 1:1000
    Immunofluorescence (Immunocytochemistry) 1:1600 - 1:6400
    Flow Cytometry (Fixed/Permeabilized) 1:400 - 1:1600
    Chromatin IP 1:100
    Chromatin IP-seq 1:100

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    实验步骤

    Specificity / Sensitivity

    LMO2 (E8K6I) Rabbit Monoclonal Antibody recognizes endogenous levels of total LMO2 protein. This antibody also recognizes a non-specific band of unknown origin at 78 kDa. Testing of this antibody with positive and negative models by Flow Cytometry and Immunofluorescence corroborated specificity of this antibody.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human LMO2 protein.

    Background

    LIM domain only protein 2 (LMO2) is a transcriptional regulator that was first identified as a proto-oncogene activated by chromosomal translocations in T-cell acute lymphocytic leukemia (T-ALL) (1). Since then, LMO2 has been found to be a master regulator essential for erythroid development, as evidenced by homozygous LMO2 knockouts resulting in embryonic lethality in mice (2). LMO2 is an intrinsically unstructured protein that does not bind DNA directly, but rather acts as a scaffolding protein that recruits various transcription factors via its tandem cysteine-rich LIM domains to form a multi-protein DNA binding complex (3,4). The LMO2 complex plays a major role in hematopoiesis and was originally shown to consist of the transcription factors TAL1, E47, and GATA-1 in erythroid lineage cells, but variations of this complex may contain alternate transcription factors including LYL1, TAL2, GATA-2, and GATA-3 (5-9). The LMO2 complex also requires interaction with LIM-domain binding protein 1 (LDB1), which is necessary for LMO2 protein stability (10-11). In addition to hematopoietic tissue, LMO2 is also expressed in embryonic brain tissue, where it associates with BEX2 and the transcription factor NSCL-2 (12). Aberrant LMO2 expression is observed in several types of hematopoietic cancers, including large diffuse B-cell lymphoma (DLBCL), B-cell acute leukemia, (B-ALL), acute myeloid leukemia (AML), and T-ALL (13-16). LMO2-mediated T-ALL is primarily caused by the translocation t(11;14)(p13;q11) with the TCRD/A gene from chromosome 14q11, or the t(7;11)(q35;p13) translocation involving TCRB from 7q35 (1). In addition to hematopoietic cancers, overexpression of LMO2 in prostate stromal cells also facilitates prostate cancer progression by inducing expression of Interleukin-11 (IL-11), which stimulates STAT3 signaling in these cells (17).
    1. Boehm, T. et al. (1991) Proc Natl Acad Sci U S A 88, 4367-71.
    2. Warren, A.J. et al. (1994) Cell 78, 45-57.
    3. Chambers, J. and Rabbitts, T.H. (2015) Open Biol 5, 150062.
    4. Lécuyer, E. et al. (2007) J Biol Chem 282, 33649-58.
    5. Valge-Archer, V.E. et al. (1994) Proc Natl Acad Sci U S A 91, 8617-21.
    6. Wadman, I. et al. (1994) EMBO J 13, 4831-9.
    7. Wadman, I.A. et al. (1997) EMBO J 16, 3145-57.
    8. Osada, H. et al. (1995) Proc Natl Acad Sci U S A 92, 9585-9.
    9. Ono, Y. et al. (1998) Mol Cell Biol 18, 6939-50.
    10. Agulnick, A.D. et al. (1996) Nature 384, 270-2.
    11. Layer, J.H. et al. (2016) Mol Cell Biol 36, 488-506.
    12. Han, C. et al. (2005) Nucleic Acids Res 33, 6555-65.
    13. Natkunam, Y. et al. (2007) Blood 109, 1636-42.
    14. de Boer, J. et al. (2011) Leukemia 25, 321-30.
    15. Atay, M.H. et al. (2013) Histopathology 63, 293-4.
    16. Patel, J.L. et al. (2014) Histopathology 64, 226-33.
    17. Jiang, C.Y. et al. (2016) Oncotarget 7, 26247-58.

    Alternate Names

    Cysteine-rich protein TTG-2; LIM domain only 2; LIM domain only 2 (rhombotin-like 1); LIM domain only protein 2; LMO-2; LMO2; RBTN2; RBTNL1; RHOM2; rhombotin 2; Rhombotin-2; rhombotin-like 1; T-cell translocation gene 2; T-cell translocation protein 2; TTG2

    Database Links

    UniProt ID: P25791


    Entrez-Gene Id: 4005


    限制使用

    除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。

    专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专

    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    Alexa Fluor is a registered trademark of Life Technologies Corporation.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.